RXRX I am new investor in this one. Looks promising.

I have been in ENTA since 2015 and so far so good. Do you have a price target for Exit? Or a time frame? Thanks

Yes, 2 recently approved products, management looks strong with proven M&A success. They have money. I also like and own OCUL in same space. GL

Yes, I am in KALA. GL

Exactly. My point is that krill oil raises a question mark in therms of efficacy. Same with other omega 3s that also failed to show what vascepa was able to prove.

Acasti (ACST) recently failed their trial with the product extracted from krill oil.

And what happened? Sell the news today?

Actually Feng Zhang today updated a POC approach for Sherlock. CRISPR is going so fast!

https://static1.squarespace.com/static/5b7c640be2ccd1703a3da4d3/t/5eb16fc2089aa30974484ce5/1588686798127/COVID-19+detection+%28v.20200505%29

The “better” Sherlock now, is called CARMEN

https://www.nature.com/articles/s41586-020-2279-8

meranini buys STML
Glad I loaded STML in last dip in March

steamline rockets 151% premarket (SA)
• Privately held Menarini Group has agreed to acquire Stemline Therapeutics (NASDAQ:STML) for $12.50 per share, consisting of $11.50 in cash plus one contingent value right (CVR) that will pay $1.00 in cash upon the completion of the first sale of Elzonris (tagraxofusp) in any EU5 country (UK, France, Spain, Germany, Italy) after European Commission approval.
• The transaction, financed with cash on hand, should close this quarter.
• Friday's close was $4.75.
• Shares up 151% premarket on robust volume

I bought FOLD, ARVN, ESPR and BEAM

Qiagen adquired https://corporate.qiagen.com/newsroom/press-releases/2020/20200303_thermo_acquires_qiagen

MS is getting a crowed market with fierce competition

TG Therapeutics (NASDAQ:TGTX) launches its rolling New Drug Application (NDA) in the U.S. seeking accelerated approval for umbralisib for patients with previously treated marginal zone lymphoma (MZL) and follicular lymphoma (FL). It expects to complete the filing in H1.

“We are extremely pleased to have initiated our first NDA submission for umbralisib and to have received guidance from the FDA to include both MZL and FL in a single NDA."
Currently stock is at 52 wh

That data delay was fishy fishy LOL
AMRN the one and only

Bussy morning in the fish oil space. With these news Amrn looking even better. Nicely up pre market

How artificially? Are you saying they manipulated the trial?
I don’t think so

Yes, as I posted here, I bought at $10.50 only a few months ago, today is at $43
ARVN

After DM program drop, Not unexpected I would say...

WVE, from the literature:

"Compounds that had nine or more Sp-linkages in the gap were found to be poorly active in vitro, while compounds with uniform Rp-gaps exhibited activity very similar to that of the stereo-random parent ASOs. Conversely, when tested in vivo, the full Rp-gap compound was found to be quickly metabolized resulting in low activity"

WVE. They are about to release data on their Huntington disease program. The stock cratered -60% a few days ago after they announced discontinuation for DMD program in earlier phase. The company is working on the space of ASOs. Currently is at 52wl. I like to search for "falling angels" but this one seems to risky. Anyone has any insight? comments on it?

ARVN yes I am in. I posted here when purchased only weeks ago at $15s. But nobody else seemed interested. I bought because found it was so cheap and reminded me of ALNY at their beginnings. Today the stock is at $43. I guess anticipating good data that will come in nearly next year

TG Therapeutics (NASDAQ:TGTX) is up 24% premarket on light volume on the heels of positive results from a Phase 1/2 clinical trial evaluating the combination of ublituximab, umbralisib (U2) and venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). The data were presented at ASH in Orlando.
• The overall response rate (ORR) in evaluable patients was 87% (n=20/23) after U2 induction period at cycle 3, prior to treatment with venetoclax, including patients who failed to respond to AbbVie's (NYSE:ABBV) Imbruvica (ibrutinib). The ORR was 100% (n=13/13) after cycle 7 of the triple combo.
• U2 induction appeared to reduce the risk of tumor lysis syndrome (a large number of cancer cells die within a short period, releasing their contents in the blood, depressing calcium levels affecting the function of certain organs) associated with venetoclax.
• Ublituximab is an anti-CD20 monoclonal antibody. Umbralisib is a dual PI3K delta and CK1 epsilon inhibitor. Venetoclax, marketed as Venclexta by AbbVie and Roche (OTCQX:RHHBY), is a BCL-2 inhibitor.
• Data from a Phase 3 study, UNITY-CLL, comparing U2 to Roche's Gazyva (obinutuzumab) + chemo agent chlorambucil should be available in the coming months.
• #ASH19

BIIB stock reversed and went to $309 reaching +6%

SAGE is ever going to work? Target for depression seems odd.

As discussed here. I was considering to get in but didn’t because was so expensive. Is it a complete failure or worth a try if goes below $50?

AMRN: Oppenheimer downgrades at $7
LOL they are full of it.
I might take advantage of this manipulation and get in today.
On other note, GILD added Vascepa to NASH trial

Yes thanks. That is why I said I am waiting for further drop prior to news

SAGE
Anyone in or have an opinion? They are releasing phase 3 data for their depression drug, this Q
Waiting for further drop prior to data to possibly get in.
Thanks in advance for your comments.

ARVN offering at $22. I bought few days ago at $15.50. I sold today at $25. Good sign the price is trading way above offering price. I will rebuy if have a chance to get shares at some point below offering.
This company reminds me of ALNY beginnings

https://flashalert.me/?symbol=ARVN&source=PR&referer=https://stocktwits.com/&url=http://www.globenewswire.com/news-release/2019/11/07/1942765/0/en/Arvinas-Inc-Announces-Pricing-of-Public-Offering-of-Common-Stock.html&s3=ARVN/2019-11-06/21-41-19_000000/glob/c09dc38f22c2f37bf18a30b0a7046bbd/Arvinas-Inc-Announces-Pricing-of-Public-Offering-of-Common-Stock.html

ARVN opened +13 % on platform and phI update

http://ir.arvinas.com/news-releases/news-release-details/arvinas-presents-platform-update-including-initial-data-first/

ARVN decided to get in yesterday at $15.50
Presenting data at upcoming protein degradation conference on the 23rd-24th
Seems undervalued IMO

Thanks Dew.

ARVN Has anyone an opinion on this company? They are trading low and have news coming soon related to the results on pipeline coming from its own proprietary platform technology PROTAC (degradation of proteins). I am having a closer look at it

ACHN that is good news for us, long term investors, who swallow the nucleoside bluf but luckily bought the dip afterwards, hoping for a second chance with the platform D.

Reported today news on ENTA:
Enanta reports positive data from mid-stage EDP-938 study https://seekingalpha.com/news/3503683

Yes, I am not a trader. Thanks
Are you still owning ADXS?

Hello Dew, I know you are a long term investor in ENTA. I used to own the stock a few years ago I bought at $40s but sold at $100.
Do you think after yesterday’s news it is good time to get back in? I know next week is data for Phase 2a data on EDP-938. Would be an opportunity to get back in before data release? Or better wait? Thanks for your wait

Thanks. Same here. Holding my shares since $5.16
Will probably keep the shares until the deal is executed sometime in second half of this year and automatically converts to aprox $48 per share

Advaxis (NASDAQ:ADXS) is down 16% after hours in reaction to its planned stock offering. Price, volume and terms have yet to be announced.